The results demonstrated that dehydrovomifoliol may alter abnormalities in fat metabolism and consequently alleviate NAFLD by downregulating the E2F1/AKT/mTOR axis. Here, E2F1 is linked to metabolic dysfunction-associated steatotic liver disease.